Clinical Trials · NCT07154238
Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
- Phase
- N/A
- Recruitment status
- Enrolling By Invitation
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 2,546
- Start date
- Sep 2025
- Locations
- 1 site, Germany
- Primary endpoint
- Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management